Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Jessica Langston

Nurse Practitioner, Family St Thomas, VI Nurse Practitioner

NPI 1033361373 CMS profile 11214896

6500 Red Hook Plz Ste 205, St Thomas, VI 00802

Open in the dashboard

General payments

$2,772

153 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jessica Langston of St Thomas, VI is reported in the CMS Open Payments database as having received $2,772 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $108 5
2023 General $133 7
2022 General $370 23
2021 General $2,161 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Langston
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jessica Langston were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jessica Langston Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,161 $124 $35–$379 $132
2022 $370 $141 $44–$430 $149
2023 $133 $154 $49–$476 $160
2024 $108 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Novo Nordisk Inc $504 20 payments
  2. AbbVie, Inc. $297 20 payments
  3. Abbott Laboratories $241 12 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $172 11 payments
  5. Lilly USA, LLC $165 12 payments
  6. Amgen Inc. $161 4 payments
  7. OptiNose US, Inc. $145 2 payments
  8. Clarus Therapeutics Inc. $140 2 payments
  9. Kowa Pharmaceuticals America, Inc. $125 24 payments
  10. Paratek Pharmaceuticals, Inc. $125 1 payment
  11. Other $696 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,772 153 payments
Products named General payments · program years 2021–2024
  1. RYBELSUS $438 16 payments
  2. FreeStyle Libre 3 $241 12 payments
  3. UBRELVY $227 15 payments
  4. JARDIANCE Diabetes $159 10 payments
  5. Ozempic $153 12 payments
  6. JARDIANCE Diabetes $151 11 payments
  7. Xhance $145 2 payments
  8. JATENZO testosterone replacement therapy $140 2 payments
  9. JATENZO testosterone replacement therapy $140 2 payments
  10. JATENZO testosterone replacement therapy $140 2 payments
  11. Other $1,720 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,083

Median for Nurse Practitioner: 389

Drug cost

$74,595

Median for Nurse Practitioner: $21,885

Branded share of claims

25.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 35 $29,316
Ozempic Semaglutide Brand 11 $15,447
Xarelto Rivaroxaban Brand 14 $12,814
Atorvastatin Calcium Generic 91 $1,183
Amlodipine Besylate Generic 88 $1,155
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 27 $1,154
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $1,152
Rosuvastatin Calcium Generic 47 $1,014
Losartan Potassium Generic 75 $983
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 40 $880

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$16,633

Medicare's payments for the services billed

Medicare patients

217

Average age 75

Services billed

374

129 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 29%
Diabetes 27%
Cancer 18%
Chronic kidney disease 13%
Osteoporosis 10%
Ischemic heart disease 7%
Alzheimer's or dementia 6%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in U.S. Virgin Islands

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record